Comstock Capital Value Fund on Bio-Techne Corp.
Thesis
Merck KGaA agreed to acquire Bio-Techne for $73.00 per share in cash. The transaction values the life-sciences tools and diagnostics company at approximately $11 billion. The fund expects the deal to close by late 2026 if shareholder and regulatory approvals are obtained.
“The transaction is subject to shareholder, as well as regulatory approvals and is expected to close by late 2026.”
Key risks
- The announced acquisition may not be completed
- Regulatory approvals may delay closing